Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice

Clinical Cancer Research

Volumn 6, Issue 11, 2000, Pages 4373-4380

  MacGregor Schafer, Jennifer ^a   Lee, Eun Sook ^a,b   O’Regan, Ruth M ^a   Yao, Kathy ^a   Jordan, V Craig ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Korea University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; PROTEIN P53; TAMOXIFEN;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER CHEMOTHERAPY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL;

ANIMALS; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL GROWTH FACTORS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR MODULATORS; FEMALE; GENES, P53; HUMANS; LYMPHOKINES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; RECEPTORS, ESTROGEN; TAMOXIFEN; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033731641     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Tamoxifen in the treatment of breast cancer
2. Tamoxifen for early breast cancer: An overview of the randomised trials
3. Pharmacology of tamoxifen in laboratory animals
4. Clinical significance of tamoxifen withdrawal response
5. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer
6. Tamoxifen-induced tumor stimulation and withdrawal response
7. Oestrogen receptor: A stable phenotype in breast cancer
8. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer
9. ARIMI-DEX: A potent and selective aromatase inhibitor for the treatment of advanced breast cancer
10. A human cell line from a pleural effusion derived from a breast carcinoma
11. MCF-7: The first hormone-responsive breast cancer cell line
12. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice
13. Human breast cancer in the athymic nude mouse: Cytostatic effects of long-term antiestrogen therapy
14. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration
15. Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro
16. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens
17. Estrogen receptor mutagenesis and hormone resistance
18. Expression of estrogen receptor variants
19. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth
20. Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen
21. Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene
22. Database of p53 gene somatic mutations in human tumors and cell lines
23. p53, the cellular gatekeeper for growth and division
24. Establishment and characterization of a cell line of human breast carcinoma origin
25. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
26. Short- and long-term estrogen deprivation of T47D human breast cancer cells in culture
27. Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro
28. p53 and survival in early onset breast cancer: Analysis of gene mutations, loss of heterozygosity and protein accumulation
29. Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer
30. TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc-binding domains
31. Cell cycle-dependent regulation of nuclear p53 traffic occurs in one subclass of human tumor cells and in untransformed cells
32. Evidence for a novel pituitary factor that potentiates the mitogenic effect of estrogen in human breast cancer cells
33. Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture
34. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long- term absence of estrogens
35. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines
36. Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions
37. An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein
38. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: A model to study the tumoristatic action of tamoxifen
39. Antiestrogenic action of toremifene on hormone-dependent -independent, and heterogeneous breast tumor growth in the athymic mouse
40. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182, 780 on endometrial cancer growth
41. Relationship of tamoxifen dose and the growth of tamoxifen-stimulated tumors
42. Response-specific antiestrogen resistance in a newly characterized MCF- 7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen
43. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo
44. Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro
45. Hormonal regulation of c-erbB-2 oncogene expression in breast cancer cells
46. Bcar1/p130Cas protein and primary breast cancer: Prognosis and response to tamoxifen treatment
47. BCAR1, a human homologue of the adaptor protein p130Cas, and antiestrogen resistance in breast cancer cells
48. p53 Mutation and tamoxifen resistance in breast cancer
49. p53 Protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer
50. Phenol red in tissue culture media is a weak estrogen: Implications concerning the study of estrogen-responsive cells in culture
51. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: Importance of hydroxyl group and side chain positioning for biological activity
52. Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation
53. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines
54. Selective promoter usage of the human estrogen receptor-α gene and its regulation by estrogen
55. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient
56. Clinical pharmacology of tamoxifen in patients with breast cancer: Comparison of traditional and loading dose schedules
57. Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer
58. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474
59. Anti-oestrogen therapy for breast cancer: A trial of tamoxifen at two dose levels
60. Biologic activity of tamoxifen at low doses in healthy women
61. Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women
62. Regulation of angiogenesis in tamoxifen-stimulated breast tumors by the pure antiestrogen ICI 182, 780
63. Prolonged treatment of breast cancer cells with antiestrogens increases the activating protein-1-mediated response: Involvement of the estrogen receptor
64. Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens
65. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens
66. Comparative analyses of mechanistic differences among antiestrogens